SEC

How Five Prime suitor Amgen battled multiple companies for the biotech—and won
How Five Prime suitor Amgen battled multiple companies for the biotech—and won
Fierce Biotech
Amgen
M&A
Five Prime Therapeutics
SEC
oncology
Flag link:
SEC charges uBiome co-founders with $60M securities fraud
SEC charges uBiome co-founders with $60M securities fraud
MedCity News
SEC
uBiome
securities fraud
Flag link:
Biotech scandal drags on as the feds only score partial victory against execs charged with cooking the books
Biotech scandal drags on as the feds only score partial victory against execs charged with cooking the books
Endpoints
SEC
Osiris Therapeutics
Flag link:
SEC awards $2.5M to Orthofix whistleblowers
SEC awards $2.5M to Orthofix whistleblowers
Mass Device
Orthofix
whistleblowers
devices
SEC
FCPA
Flag link:
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Fierce Biotech
Poseida Therapeutics
solid tumors
CAR-T
SEC
prostate cancer
Flag link:
Alexion Pharmaceuticals Agrees to $21.5 Million Settlement With SEC in Bribery Case
Alexion Pharmaceuticals Agrees to $21.5 Million Settlement With SEC in Bribery Case
Motley Fool
Alexion Pharmaceuticals
SEC
bribery
FCPA
Flag link:
Novartis inks settlements worth $347M with DOJ, SEC over foreign doctor payments, records keeping
Novartis inks settlements worth $347M with DOJ, SEC over foreign doctor payments, records keeping
Fierce Pharma
Novartis
DOJ
kickbacks
physicians
FCPA
SEC
Flag link:
Report: Congressman wants SEC investigation into Gilead Covid-19 data leak
Report: Congressman wants SEC investigation into Gilead Covid-19 data leak
MedCity News
legal
SEC
Gilead Sciences
remdesivir
NASDAQ
COVID-19
Flag link:
Will COVID-19 Derail New Drugs?
Will COVID-19 Derail New Drugs?
Motley Fool
COVID-19
SEC
regulatory
clinical trials
Flag link:
Aduro stung as Novartis drops work on STING drug
Aduro stung as Novartis drops work on STING drug
Fierce Biotech
Aduro BioTech
Novartis
SEC
ADU-S100
Flag link:
Bankrupt Insys offers to turn out its almost empty pockets for plaintiffs
Bankrupt Insys offers to turn out its almost empty pockets for plaintiffs
Fierce Pharma
Insys
bankruptcy
SEC
DOJ
Flag link:
As Osiris moves on from fraudulent past, one exec settles up with SEC
As Osiris moves on from fraudulent past, one exec settles up with SEC
Endpoints
Osiris Therapeutics
SEC
Flag link:
Mylan Stock Dives On $30 Million Settlement In EpiPen Scandal
Mylan Stock Dives On $30 Million Settlement In EpiPen Scandal
Investors Business Daily
Mylan
SEC
EpiPen
Flag link:
SEC Charges TherapeuticsMD for Selectively Disclosing Info From FDA Meeting
SEC Charges TherapeuticsMD for Selectively Disclosing Info From FDA Meeting
RAPS.org
TherapeuticsMD
SEC
FDA
Flag link:
BIO tells SEC: do away with quarterly reports for small biotechs
BIO tells SEC: do away with quarterly reports for small biotechs
Endpoints
BIO
SEC
biotechs
quarterly reports
Flag link:
BioSig raises $9m
BioSig raises $9m
Mass Device
SEC
BioSig Technologies
Pure EP System
electrocardiography
Flag link:
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
TheStreet.com
SEC
FTC
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Biotechs Scramble to Get IPOs Moving Now That Government Is Open
Biotechs Scramble to Get IPOs Moving Now That Government Is Open
BioSpace
IPOs
SEC
Flag link:
As shutdown stalls IPOs, companies mull creative paths to market
As shutdown stalls IPOs, companies mull creative paths to market
Biopharma Dive
SEC
NASDAQ
IPOs
Flag link:
Uncertainty Grows for Biotech as Government, FDA Shutdown Drags On
Uncertainty Grows for Biotech as Government, FDA Shutdown Drags On
Xconomy
government shutdown
FDA
SEC
Flag link:

Pages